MPI STANNOUS DIPHOSPHONATE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MPI Stannous Diphosphonate is an injectable diagnostic agent developed by GE HealthCare, approved in 1977. The product functions as a radiopharmaceutical for diagnostic imaging, though specific indications are not documented in available data. This is a legacy small-molecule imaging agent with established clinical utility in nuclear medicine.
LOE Approaching
As a legacy diagnostic agent approaching loss of exclusivity with moderate competitive pressure (30%), team roles are likely focused on managed decline and operational efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and a product in LOE-approaching status, career opportunities on this team are severely limited and typically involve defending existing business rather than driving growth. Professionals joining this portfolio should expect a focus on margin protection, operational efficiency, and potential transition or discontinuation planning rather than career acceleration.
Product Manager
Worked on MPI STANNOUS DIPHOSPHONATE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.